Epithalon

also known as: Epitalon, Epithalamin, AEDG

A synthetic pineal tetrapeptide from the Khavinson group (St. Petersburg) — the only peptide with published data claiming telomerase activation and telomere elongation in human cell models.

A short tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal extract epithalamin, developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology and reported to induce telomerase activity and telomere elongation in human somatic cells.

Mechanism of action

Reported to activate telomerase reverse transcriptase (TERT) in somatic cells, increasing telomerase activity ~33% in human fibroblasts at 1 μM and elongating telomeres. Also reported to normalize melatonin secretion, cortisol rhythm, and gonadotropin profiles in aged rodents. Purported lifespan extension of 13.3% in rats with chronic administration. The underlying mechanism at the molecular level remains incompletely characterized and Western independent verification is limited.

Primary uses

Longevity research (primarily Russian literature)
Community anti-aging cycles
Pineal/circadian research

Typical dosing

5–10 mg daily for 10–20 days (1–2× yearly) (subcutaneous)

Community cycling protocols. No clinical standard outside of Russian geriatric clinics.

Regulatory status

Not approved in any major jurisdiction. Epithalamin (the parent extract) is marketed as a food supplement / bioregulator in Russia. Extensive Russian-language literature; limited Western independent replication of the telomerase findings.

References

[pubmed] Khavinson VK, Bondarev IE, Butyugov AA. "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bull Exp Biol Med, 2003;135:590-592.
[pubmed] Anisimov VN, et al. "Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice." Biogerontology, 2003;4:193-202.

Related peptides

SS-31 (Elamipretide)

The first FDA-approved mitochondria-targeted peptide therapeutic — approved September 2025 as Forzinity for Barth syndrome, with broader investigation in heart failure, macular degeneration, and aging.

MOTS-c

A mitochondrially encoded peptide studied for its effects on metabolic homeostasis, insulin sensitivity, and exercise capacity.

Humanin

A mitochondrial-derived peptide with neuroprotective, metabolic, and anti-apoptotic activity — one of the first signaling peptides identified as encoded by mitochondrial DNA.

DSIP

An endogenous 9-amino-acid peptide named for its ability to induce delta-wave sleep in early rabbit experiments, with broader effects on stress response, pain modulation, and circadian regulation.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.